Overview

Tech Summary

Promoter Holding

Posts

DRREDDY

40123456789,301234567891012345678940123456789.0012345678900123456789
+113.05 (+2.69%)
The current prices are delayed.Login/Sign Up to see live prices.
Previous Close: 4200.95
1D
5D
1M
3M
1Y
5Y
Today's low
4253.35
Today's high
4380.9
52 week low
3654
52 week high
5614.6
Volume
956288
About
Tech Summary
DMA(12)
₹4257.97
DMA(50)
₹4185.78
DMA(100)
₹4183.94
DMA(200)
₹4469.88
Fund Summary
Market Cap
₹71784.96 Cr.
Enterprise Value
₹73332.86 Cr.
No. of Shares
16.64
P/E
32.9
RoE
11.53
Debt/Equity
0.17
Valuations
PE Chart
4042444648
PB Chart
3.43.63.8
Promoter Holdings
Public : 12.12%
FII : 25.16%
DII : 24.78%
Promoter : 26.72%
Others : 0%
Charts
Debt/Equity
0.150.200.250.300.350.40
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
ROE vs ROCE
810121416
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
ROE
ROCE
Revenue vs Profitability (1000Cr.)
5101520
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
Revenue
Profit
Margins(%)
10152025
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
Net Margin
Gross Margin
About
Hero Img
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Price Target Potential
Brokerage
Sharekhan
Nirmal Bang
Target
5550
5349
Potential
27.95%
22.74%
Stock Sentiments
83% Bullish
17% Bearish
77 live trades of Rs. 8,174,658.15
T
tdivsha
 
Reputation: 0 • 
Jan 27 8:58 PM
DRREDDY
30 Qty (S) Trade entered-₹316.5
T
tdivsha
 
Reputation: 0 • 
Jan 27 8:57 PM
DRREDDY
10 Qty (S) Trade entered-₹103
Posts by FrontPage Users
NewsBot-display-image
Reputation: 29,719  •  Jan 28 4:28 AM
Buy Dr. Reddy’s Laboratories, target of Rs 5460: Sharekhan
Buy Dr. Reddy’s Laboratories, target of Rs 5460: Sharekhan
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5460 in its research report dated January 25, 2023.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Jan 27 3:38 PM
Dr Reddy’s Q3 consolidated profit jumps 77%; what should investors do with the stock?
Dr Reddy’s Q3 consolidated profit jumps 77%; what should investors do with the stock?
Dr Reddy’s Laboratories reported a 77 percent growth in consolidated net profit at Rs 1,247 crore for the quarter ended December 31, 2022 as against Rs 707 crore a year ago. On a sequential basis, the profit grew 12 percent.
Moneycontrol
Like
Comment
Share
Add a comment
Divya Sreejith-display-image
Reputation: 396  •  Jan 27 4:02 AM
Like
Comment
Share
Add a comment
Accurate Trading -display-image
Reputation: 8,316  •  Jan 26 11:02 PM

🟢🟢 Dr.reddys labs falling wedge formation on daily chart and Results are out in positive ways so keep ur radar on Friday on this script.

Results:-
Dr Reddys Lab December 2022 (Quarterly) PAT at
Rs 1,244 crore vs Rs 709 crore YoY. Income at Rs
6,790 crore vs Rs 5,338 ......read more
Chartbusters - 25238439
14 Likes
1 Comment
Share
Add a comment
Add a comment
Add a comment
B
Reputation: 196  •  Jan 21 1:31 AM
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Jan 20 5:08 PM
Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate
Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate
Following completion of the full set of clinical studies, Dr Reddy's said it will now prepare to file in the US, European Union and other regions for approval of 'DRL_RI'.
Moneycontrol
1 Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Jan 20 4:58 PM
Dr Reddy's completes clinical studies of key biosimilar, step closer to launching in US, Europe
Dr Reddy's completes clinical studies of key biosimilar, step closer to launching in US, Europe
The company will collaborate with partner Fresenius Kabi to commercialise the proposed biosimilar for treating illnesses such as arthritis and non-Hodgkin's lymphoma in the US but plans to take the product directly to EU and other regions
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Jan 14 1:03 AM
Dr Reddy's acquires trademark rights for Pfizer's breast cancer drug
Dr Reddy's acquires trademark rights for Pfizer's breast cancer drug
The drug will be retailed in the Indian market at an 85 percent reduction from the current MRP to increase affordability and access, the pharma company has said
Moneycontrol
Like
Comment
Share
Add a comment
Shashwat Jain-display-image
Reputation: 1,663  •  Jan 9 2:28 AM

Head and shoulder in #DRREDDY
Time Frame = 15 mins
Chartbusters - chart - 22049854
Like
Comment
Share
Add a comment
 price action trading-display-image
Reputation: 22,774  •  Jan 4 2:58 AM
1 Like
Comment
Share
Add a comment
Expert Opinions-display-image
Reputation: 5,460  •  Jan 3 5:21 AM

DR REDDY
Drrreddy Chart Foe Tommorow
Check It
Chartbusters - chart - 21216556
3 Likes
Comment
Share
Add a comment
Wise Weath Advisor-display-image
Reputation: 1,680  •  Dec 31, 2022 7:05 PM
Like
Comment
Share
Add a comment
Sitesh-display-image
Reputation: 684  •  Dec 30, 2022 12:44 AM

Bhai log....PE lene ka waqt agaya.
4100 comming soon.
Option chain dekh lo.price action dekh lo.
Disclaimer- do your own research before taking any trade. Formalities 😎.
Baki jisko position lena hai wo lechuka 🙋
Chartbusters - chart - 20869050
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Dec 29, 2022 5:13 PM
Claims against Dr Reddy's over Revlimid in US dismissed
Claims against Dr Reddy's over Revlimid in US dismissed
In a regulatory filing, the company said on December 22, 2022 and December 27, 2022, the plaintiffs voluntarily dismissed Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories, Inc. respectively, from the case.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Dec 29, 2022 4:33 PM
Dr Reddy's shares gain after US dismisses claims against Revelimid
Dr Reddy's shares gain after US dismisses claims against Revelimid
Revlimid, also known as lenalidomide, is an oral drug that is used for the treatment of multiple myeloma or blood cancer
Moneycontrol
Like
Comment
Share
Add a comment
Mehta-display-image
Reputation: 4,718  •  Dec 29, 2022 3:24 PM

Earlier also i had shared a detaield study on Dr.Reddy
In continuation with the above post,
the levels of 4280-4300 are very crucial.Remember friends the support and resistance levels are always flexible zones and not iron bars that cANT be broken
As u can see in the ch......read more
Chartbusters - chart - 20703574
Like
1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Dec 22, 2022 11:48 PM
Buy Dr. Reddy’s Laboratories; target of Rs 5460: Sharekhan
Buy Dr. Reddy’s Laboratories; target of Rs 5460: Sharekhan
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5460 in its research report dated December 21, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
Traders Point India-display-image
Reputation: 1,288  •  Dec 22, 2022 6:34 AM

DRREDDY Both Side Potential For Intraday Tommorow.
Chartbusters - chart - 19738682
1 Like
Comment
Share
Add a comment
Elliott Wave-display-image
Reputation: 26,571  •  Dec 17, 2022 2:43 AM

#DRREDDY 4630 to 4265

New Sell Only below Black TL
Chartbusters - chart - 19222323
5 Likes
Comment
Share
Add a comment
Traders Point India-display-image
Reputation: 1,288  •  Dec 16, 2022 4:37 AM

DRREDDY rejection from trendline in daily frame 15 min head and shoulder breakdown gives double confirmation.
Chartbusters - chart - 19063041
1 Like
Comment
Share
Add a comment
Abhishek Gupta-display-image
Reputation: 808  •  Dec 12, 2022 5:35 PM

#DRREDDY moving in Rising wedge pattern support by all moving averages making it more strong support area. Take your call accordingly. Thanks..
Chartbusters - chart - 18534157
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Dec 11, 2022 5:11 PM
Vaishali Parekh on PSU Bank: Punjab & Sind Bank & Central Bank up 30-40% in a week. Should you buy, sell or hold?
Vaishali Parekh on PSU Bank: Punjab & Sind Bank & Central Bank up 30-40% in a week. Should you buy, sell or hold?
Nifty after peaking out near 18887 levels, witnessed some profit booking, led by the major frontline IT stocks witnessing some profit booking and shedding their gains from their peak levels, accompanied by the Metal sector also lost some momentum.
The Economic Times
Like
Comment
Share
Add a comment
Traders Point India-display-image
Reputation: 1,288  •  Dec 9, 2022 6:43 AM

DRREDDY Inverted Head and Shoulder Long Above Resistance Zone, Book Near Targets Marked
Chartbusters - chart - 18320152
Like
Comment
Share
Add a comment
N

Buy now for target of 1%- 0.8 %.
We can now see pivot breakout and then boom.
1 Like
Comment
Share
Add a comment
Equity And Option Trader-display-image
Reputation: 46,428  •  Nov 16, 2022 10:35 PM

1. After a decline from 5600 odd levels to 3700 odd levels, stock is in short term uptrend.
2. As we can see, a Bearish Flag is in making. Currently it's consolidating and a decisive Break Down (most probably) may happen anytime soon.
3. Rejection is also evident from t......read more
Chartbusters - chart - 16208162
Like
2 Comments
Share
Add a comment
Nikhil Sai-display-image
Reputation: 488  •  Nov 8, 2022 6:31 AM

#DRREDDY - Short-Term Opportunity

On Daily Timeframe, made a Double Bottom and gave breakout.
Testing the resistance(earlier) again!
TGT: 4830 (next resistance as well)
SL: 4440
Company also posted the highest ever sales and operating profit in recent quarter results, therefore ......read more
3 Likes
Comment
Share
Add a comment
Mehta-display-image
Reputation: 4,718  •  Nov 7, 2022 3:36 PM

bearish view only for educational purpose
chart is self explanatory
Chartbusters - chart - 15427610
Like
1 Comment
Share
Add a comment
Sameer -display-image
Reputation: 8,335  •  Nov 2, 2022 2:50 PM

02-11-22
DRREDDY BUY NOV CE 4600 (Intraday)
only above 102.5

1 Like
3 Comments
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Nov 2, 2022 12:53 AM
Buy Dr Reddy’s Labs; target of Rs 5180: Motilal Oswal
Buy Dr Reddy’s Labs; target of Rs 5180: Motilal Oswal
Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5180 in its research report dated October 29, 2022.
Moneycontrol
1 Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Nov 2, 2022 12:13 AM
Buy Dr Reddy's Laboratories; target of Rs 5215: ICICI Direct
Buy Dr Reddy's Laboratories; target of Rs 5215: ICICI Direct
ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 5215 in its research report dated October 29, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
Nifshots -display-image
Reputation: 1,231  •  Nov 1, 2022 5:42 PM
2 Likes
1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Nov 1, 2022 4:43 AM
Buy Dr. Reddy's Laboratories; target of Rs 4900: Prabhudas Lilladher
Buy Dr. Reddy's Laboratories; target of Rs 4900: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated October 31, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
TradingEssentials-display-image
Reputation: 432  •  Nov 1, 2022 12:19 AM

Nifty Pharma ..after topping in July 2021.. is now showing signs of come up.. last 5 columns (from RHS) shows Triple top buy.. implying the sector is gaining strength .. so allocation to Pharma sector should be increased for at least next 1 year or until the pattern changes to ne......read more
5 Likes
3 Comments
Share
Add a comment
Nifshots -display-image
Reputation: 1,231  •  Oct 31, 2022 5:54 PM

#DRREDDY 4340 Strong Support. Bouncing From 4340,
Like
Comment
Share
Add a comment
Market Buzz-display-image
Reputation: 1,439  •  Oct 31, 2022 5:50 PM

#DRREDDY High Risk Trade
Buy 4600CE@50-52(Near)
Target: 60/70/85++
Stop loss:30
Hold till Expiry or Exit as per your risk appetite
Disclaimer: Its my personal view only. Do your own analysis before investing.
Like
6 Comments
Share
Add a comment
Elliott Wave-display-image
Reputation: 26,571  •  Oct 31, 2022 5:07 PM

#DRREDDY Reason to call closed

Horrible Move Expecting downside
Chartbusters - chart - 14939869
6 Likes
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Oct 31, 2022 3:33 PM
Dr Reddy’s surges as Revlimid generic helps drug maker sprint past estimates
Dr Reddy’s surges as Revlimid generic helps drug maker sprint past estimates
Sales from the North American market, nearly 50 percent of overall sales, grew 48 percent at Rs 2,800 crore for September quarter
Moneycontrol
Like
Comment
Share
Add a comment
 price action trading-display-image
Reputation: 22,774  •  Oct 31, 2022 4:18 AM

triangle pattern breakout and retesting buy above pday high
next resistance levels
Chartbusters - chart - 14894555
13 Likes
11 Comments
Share
Add a comment
Accurate Trading -display-image
Reputation: 8,316  •  Oct 29, 2022 1:17 AM


Dr Reddys Laboratories September 2022
(Quarterly) PAT at Rs 1,114 crore vs Rs 996 crore
YoY. Revenue at Rs 6,332 crore vs Rs 5,787 crore yoy.

Proud to be dr.reddys employee😎
2 Likes
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Oct 28, 2022 10:23 PM
Dr Reddy's Q2 result | Consolidated PAT grows 12 % YoY to Rs 1,113 crore
Dr Reddy's Q2 result | Consolidated PAT grows 12 % YoY to Rs 1,113 crore
Dr Reddy's Q2 result: The drugmaker reported a 9% YoY increase in consolidated revenues at Rs 6,305 crore for the reported quarter
Moneycontrol
Like
Comment
Share
Add a comment
S
Reputation: 16  •  Oct 28, 2022 4:18 PM
Like
Comment
Share
Add a comment
Elliott Wave-display-image
Reputation: 26,571  •  Oct 28, 2022 2:02 AM

#DRREDDY 4249 to 4525

TSL 4214 and holding for tg
Chartbusters - chart - 14794787
5 Likes
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,719  •  Oct 27, 2022 10:18 PM
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop net profit on weak US biz
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop net profit on weak US biz
Dr Reddy’s North American operations will set the tone for the September quarter performance, as likely price erosion will trigger a decline in sales on a year-on-year basis
Moneycontrol
Like
Comment
Share
Add a comment
Young Finance India-display-image
Reputation: 288  •  Oct 27, 2022 3:27 PM

#DRREDDY a good breakout with strength in the sector and drreddy showing good momentum as well on daily chart !!!
Chartbusters - chart - 14707801
2 Likes
Comment
Share
Add a comment
Shruti-display-image
Reputation: 23,224  •  Oct 27, 2022 3:53 AM

Tomorrow watchlist for f&o trading
According to some important instructions given in charts so read it 👍✌️
Before take any action plz research own 🙏
This post educational purpose only
4 Likes
2 Comments
Share
Add a comment
Sameer -display-image
Reputation: 8,335  •  Oct 25, 2022 2:49 PM

25-10-22
DRREDDY BUY OCT CE 4500 (Intraday)
only above 4

Like
4 Comments
Share
Add a comment
Load More Posts